Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon beta-1a · 1 trial · 1 indication
ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).
| Arm | Type | Description |
|---|---|---|
| Treatment arm - Rebif® | EXPERIMENTAL | Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw) |
| Placebo arm | PLACEBO_COMPARATOR | Subjects in this arm received placebo |
| Name | Type | Description |
|---|---|---|
| Interferon beta-1a | DRUG | Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc) |
| Placebo | DRUG | The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way |
Inclusion Criteria: * Subjects aged between 50 and 75 years * Subjects diagnosed with AD, according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) * Subjects with MMSE score of 20 to 26 (inclusive) * Subjects supervised by a caregiver * Subjects who have been giv...
Top 20 of 24 competitors
Interferon beta-1a is being investigated as a treatment for Alzheimer's Disease. It is currently in Phase 2 clinical development for this indication. The drug is being studied in a pilot trial to assess its effects in patients with Alzheimer's Disease.
Interferon beta-1a is being developed by Merck KGaA, a company traded under the ticker MKGAF. The company is conducting clinical research to evaluate the drug's potential in treating Alzheimer's Disease.
Interferon beta-1a is in Phase 2 clinical development for Alzheimer's Disease. It is an investigational drug and has not been approved for this use. One Phase 2 trial has been completed to evaluate its safety and efficacy.
Interferon beta-1a has been studied in a completed Phase 2 trial with the identifier NCT01075763. This trial, titled 'A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease,' enrolled 42 participants in Italy and was placebo-controlled and double-blind.
Interferon beta-1a is a specific form of interferon beta. It is being studied for Alzheimer's Disease, a different condition from the multiple sclerosis indications for which other interferon beta products are commonly known.